Research programme: influenza virus like particle vaccines - Icosavax
Alternative Names: Influenza VLP vaccines - IcosavaxLatest Information Update: 03 May 2024
At a glance
- Originator University of Washington
- Developer Icosavax; University of Washington
- Class Influenza virus vaccines; Protein vaccines; Synthetic vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Influenza virus infections
Most Recent Events
- 06 Jan 2023 Icosavax executes patent license for influenza neuraminidase antigens from the University of Washington and the NIH
- 29 Mar 2022 Preclinical trials in Influenza virus infections (Prevention) in USA (Parenteral) (Icosavax pipeline, April 2022)
- 07 Jan 2022 Icosavax exercises option for non-exclusive patent license from the University of Washington and US Department of Human and Health Services (HHS) for use of two-component VLP platform for Influenza infections